1. Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice – results from the ElderTac study
   Wolfgang M. Brueckl et al, 2018, BMC Cancer CrossRef
2. Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer
   Satoshi Igawa et al, 2020, Investigational New Drugs CrossRef
3. Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis
   Hye Duck Choi et al, 2020, PLOS ONE CrossRef
4. Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors
   Taihei Ono et al, 2020, Investigational New Drugs CrossRef
5. 177Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
   Finn E. von Eyben et al, 2021, Biomedicines CrossRef
6. Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China
   Yang Wang et al, 2021, Pharmacology CrossRef
7. The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China
   Mingjun Rui et al, 2022, Frontiers in Pharmacology CrossRef